Hot Seat: How Experts Are Integrating the Latest Practice-Changing Data Into Their Breast Cancer Clinics

Thanks for your interest in this podcast. Please read this important program information before listening.

Episode Description

In this podcast, experts Tiffany A. Traina, MD, FASCO; Nour Abuhadra, MD; Joshua Z. Drago, MD, MS; Ruth O’Regan, MD; Vered Stearns, MD, FASCO; Neil Vasan, MD, PhD; and Anna Weiss, MD, discuss the evolving treatment landscape across breast cancer subtypes and lines of care. Gamified case-based discussion will focus on integrating the latest practice-changing data into clinical practice to optimize care for patients with breast cancer.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Evaluate recent evidence from pivotal clinical trials assessing novel agents and expanded indications for existing therapies in patients with breast cancer
• Incorporate potentially practice-changing data into individualized treatment plans for patients with breast cancer

Acknowledgment of Educational Grant Support

This activity is supported by an educational grant from Revolution Medicines.

Chair:

Tiffany A. Traina, MD, FASCO

Associate Attending Physician
Vice Chair, Oncology; Department of Medicine
Section Head, Triple-Negative Breast Cancer Clinical Research Program
Memorial Sloan Kettering Cancer Center
Associate Professor of Medicine, Weill Cornell Medicine
New York, NY

Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Aktis Oncology, AstraZeneca, BioNTech SE, Daiichi Sankyo, Ellipses Pharma, Exact Sciences, Genentech/Roche, Gilead Sciences, Merck, Pfizer, Stemline Therapeutics, TerSera, Veracyte; Grant/Research Funding (to institution): Astellas Pharma, AstraZeneca, BioNTech SE, Daiichi Sankyo, Genentech/Roche, Pfizer

Nour Abuhadra, MD

Assistant Professor
Director, Rare Breast Cancer Program, Department of Medicine
Co-Section Head, Triple-Negative Breast Cancer Clinical Research Program Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosure: Nour Abuhadra, MD, has no relevant financial relationships with ineligible companies.

Joshua Z. Drago, MD, MS

Assistant Attending Physician
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AmMax Bio, AstraZeneca, Genagon Therapeutics, MEDACorp, NuProbe, Revelio Therapeutics; Grant/Research Funding (to institution): AstraZeneca, Jazz Pharmaceuticals, Merck & Co, Orum Therapeutics

Ruth O’Regan, MD

Chair, Department of Medicine
Charles A. Dewey Professor of Medicine and Oncology
University of Rochester Medical Center School of Medicine and Dentistry
Associate Director, Education and Mentoring
Wilmot Cancer Institute
Rochester, NY

Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Biotheranostics, Gilead, Lilly, Puma, Regor Therapeutics; Grant/Research Funding: Novartis, Puma

Vered Stearns, MD, FASCO

Professor of Medicine
Director for Translational Breast Cancer Research
Interim Chief, Breast Medical Oncology Hematology and Medical Oncology
Associate Director for Clinical Research, Sandra and Edward Meyer Cancer Center
Weill Cornell Medicine
New York, NY

Disclosures: Chair, DSMB: AstraZeneca

Neil Vasan, MD, PhD

Assistant Professor
Director, Breast Cancer Translational Research
Department of Medicine, NYU Grossman School of Medicine
Perlmutter Cancer Center, NYU Langone Health
New York, NY

Disclosures: Advisor, Consultant, Speaker Honoraria Recipient: Apertor Pharmaceuticals, Avenzo Therapeutics, Reactive Biosciences, Scorpion Therapeutics; Grant/Research Funding: Gilead; Executive Role: Meliora Therapeutics (member of SAB); Royalty of Patent Benefits: Wolters Kluwer; Ownership Interests in Privately Held Companies: Heligenics, Meliora Therapeutics, Reactive Biosciences

Anna Weiss, MD

Associate Professor
Department of Surgery, Oncology
University of Rochester Medical Center
Rochester, NY

Disclosure: Anna Weiss, MD, has no relevant financial relationships with ineligible companies.

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

The staff of Physicians’ Education Resource^®, LLC, have no relevant financial relationships with ineligible companies.

This podcast, including the narration, was developed by PER^® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.

To learn more about this topic, including information on the treatment of a pre-menopausal woman with ESR1-mutant, HR- positive, HER2-negative breast cancer, go to https://www.gotoper.com/cfs25breasthotseat-enduring.

Release Date

February 2, 2026

Expiration Date

February 2, 2027

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.